Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 2/20 | 0.45 |
| ▸ | AR | P10275 | 7/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31498643 | 0.88 | PGR (0.45) | PGRAREPHX2S1PR1KCNJ1 | |
| SCHEMBL19833654 | 0.85 | PGR (0.39) | PGRARFFAR4EPHX2S1PR1 | |
| SCHEMBL19833661 | 0.85 | PGR (0.39) | PGRARFFAR4EPHX2S1PR1 | |
| SCHEMBL19833670 | 0.84 | PGR (0.38) | PGRARKCNJ1KCNH2 | |
| SCHEMBL3197384 | 0.80 | AR (0.66) | PGRAR | |
| SCHEMBL3200817 | 0.77 | AR (0.70) | PGRAR | |
| SCHEMBL21028817 | 0.77 | AR (0.37) | PGRARKCNJ1KCNH2 | |
| SCHEMBL31515461 | 0.77 | EPHX2 (0.48) | PGRAREPHX2 | |
| SCHEMBL1980445 | 0.76 | AR (0.51) | PGRAR | |
| SCHEMBL3186123 | 0.76 | AR (0.68) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934278-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-03-02 | — | — | US | disclosed |
| EP-3490977-B1 | CYCLOBUTANE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED POTASSIUM CHANNELS | AUTIFONY THERAPEUTICS LTD (GB) | 2020-11-25 | — | — | EP | disclosed |
| US-20190161479-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934278-B2 | Compounds | KCNA3, KCNN3, KCND3 | PGR 3901/4885AR 3581/4885FFAR4 929/4885 |
| US-20190161479-A1 | NOVEL COMPOUNDS | KCNN3, KCNA3, KCND3 | PGR 4302/4885AR 4286/4885FFAR4 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.